MAM
ELEV

Marquette Asset Management’s Elevation Oncology ELEV Stock Holding History

Marquette Asset Management’s Portfolio ELEV Stock Details ELEV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-38,951
Closed -$44K – 236
2022
Q3 		$44K Hold
38,951
– – 0.01% 144
2022
Q2 		$55K Hold
38,951
– – 0.02% 159
2022
Q1 		$98K Buy
38,951
+29,945
+333% +$120K 0.02% 150
2021
Q4 		$54K Buy
+9,006
New +$62.2K 0.01% 181

Other funds holding ELEV

ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
QUSVM
Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Marquette Asset Management's ELEV Position: Q4 2022 in Review

Marquette Asset Management sold out of Elevation Oncology (ELEV) in Q4 2022, closing a stake of 38,951 shares — an estimated $44K sold.

Marquette Asset Management first reported a position in ELEV in Q4 2021 and held it in 4 quarters. The position peaked at $98K in Q1 2022. 27 funds tracked by Wall St. Rank hold ELEV as of Q4 2022.

  • Marquette Asset Management reported no remaining Elevation Oncology position as of Q4 2022 after selling out during the quarter.
  • Marquette Asset Management sold 38,951 Elevation Oncology shares in Q4 2022, an estimated $44K.
  • Marquette Asset Management first reported a position in Elevation Oncology in Q4 2021 and held it in 4 quarters.
  • Marquette Asset Management's Elevation Oncology position peaked at $98K in Q1 2022.
  • 27 funds tracked by Wall St. Rank held Elevation Oncology as of Q4 2022.

Based on Marquette Asset Management's 13F filing for Q4 2022, filed 12 Jan 2023.